| Primary information |
|---|
| OV_ID | OV_527 |
| Virus Name | Adenovirus |
| Strain | OBP-301 (telomelysin) |
| Virus type | DNA |
| Virus family | Adenoviridae |
| Modification in virus genome | Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells |
| Virus alone | No |
| Virus in combination iwth drug/radiation | Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml ) |
| Immune gene induction in virus genome | No |
| Source of cell line | DS Pharma Biomedical |
| Origin of cell line | Human osteosarcoma cell line |
| Cell line | MNNG/HOS |
| Concentration of cell line | 1 |
| In-vitro toxicity | NA |
| Assay | XTT assay |
| In-vitro virus concentration | 1 MOI |
| In-vitro result | 83% cancer cell viability (calculated as relative to mock-infected group) |
| Model organism | No |
| In-vivo virus concentration | No |
| In-vivo toxicity | NA |
| In-vivo result | No response |
| Mode of delivery | NA |
| Pathway induction | OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis |
| Immunogenic effect | NA |
| Clinical trial | NA |
| PMID | 27356624 |